DeCode and FDA agree on phase III cardio trial design
The special protocol assessment (SPA) enables DeCode to proceed with the recruitment of participants for the phase III trial. The SPA is an agreement between the FDA and
ReviR Therapeutics has received a rare paediatric disease designation (RPDD) from the US Food and Drug Administration (FDA) for RTX-117, its investigational oral small-molecule therapy for Charcot-Marie-Tooth disease (CMT).